5VM
VKTX icon

5AM Venture Management’s Viking Therapeutics VKTX Stock Holding History

5AM Venture Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-189,593
Closed -$5.02M – 28
2025
Q2 		$5.02M Hold
189,593
– – 1.93% 18
2025
Q1 		$4.58M Hold
189,593
– – 1.73% 20
2024
Q4 		$7.63M Sell
189,593
-47,967
-20% -$2.74M 1.82% 18
2024
Q3 		$15M Hold
237,560
– – 3.11% 13
2024
Q2 		$12.6M Hold
237,560
– – 2.82% 11
2024
Q1 		$19.5M Sell
237,560
-347,440
-59% -$15.5M 4.36% 7
2023
Q4 		$10.9M Hold
585,000
– – 2.89% 13
2023
Q3 		$6.48M Hold
585,000
– – 1.86% 15
2023
Q2 		$9.48M Buy
585,000
+235,000
+67% +$4.92M 2.36% 11
2023
Q1 		$5.83M Buy
+350,000
New +$3.62M 1.49% 16

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

5AM Venture Management's VKTX Position: Q3 2025 in Review

5AM Venture Management sold out of Viking Therapeutics (VKTX) in Q3 2025, closing a stake of 189,593 shares — an estimated $5.02M sold.

5AM Venture Management first reported a position in VKTX in Q1 2023 and held it in 10 quarters. The position peaked at $19.5M in Q1 2024. 370 funds tracked by Wall St. Rank hold VKTX as of Q3 2025.

  • 5AM Venture Management reported no remaining Viking Therapeutics position as of Q3 2025 after selling out during the quarter.
  • 5AM Venture Management sold 189,593 Viking Therapeutics shares in Q3 2025, an estimated $5.02M.
  • 5AM Venture Management first reported a position in Viking Therapeutics in Q1 2023 and held it in 10 quarters.
  • 5AM Venture Management's Viking Therapeutics position peaked at $19.5M in Q1 2024.
  • 370 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2025.

Based on 5AM Venture Management's 13F filing for Q3 2025, filed 14 Nov 2025.